Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact

Although human papillomavirus (HPV) vaccines were initially licensed based on efficacy after three-dose regimens in women aged 15–26 years, it was recognized early in clinical development that comparable immunogenicity could be obtained after just two doses when administered to younger girls. In bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilca, Vladimir, Salmerón-Castro, Jorge, Sauvageau, Chantal, Ogilvie, Gina, Landry, Monique, Naus, Monica, Lazcano-Ponce, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078939/
https://www.ncbi.nlm.nih.gov/pubmed/29887322
http://dx.doi.org/10.1016/j.vaccine.2018.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078939/
https://www.ncbi.nlm.nih.gov/pubmed/29887322
http://dx.doi.org/10.1016/j.vaccine.2018.02.004

Ejemplares similares